TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE:MSET) (FSE:9DF) (OTCQB:MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has developed first-in-class studies to enable the…


Previous articlePT261 – Dr. Tiago Reis Marques – Ketamine, New Drugs, and the Repurposing of Current Drugs
Next articleGlutamate’s Role in Rapidly-Acting Antidepressants